Description:FIELD OF THE INVENTION
The present invention relates to the field of computational healthcare, biomedical engineering, and applied mathematics, specifically addressing the use of fractional differential equation-based multistep numerical methods for optimizing drug dosage and developing predictive healthcare models. The invention lies at the intersection of pharmaceutical sciences, precision medicine, and advanced computational modeling, where conventional integer-order approaches often fail to capture the inherent complexity, memory effects, and non-local dynamics of biological and physiological systems. By leveraging fractional calculus, the invention provides a novel mathematical and computational framework that enhances the accuracy and reliability of pharmacokinetic and pharmacodynamic modeling, thereby enabling individualized treatment strategies. The field of invention encompasses the design and implementation of fractional multistep methods to solve complex differential equations governing drug absorption, distribution, metabolism, and excretion processes in patients with varying health conditions and genetic backgrounds. Additionally, it extends to predictive healthcare applications, where fractional models are utilized to forecast disease progression, evaluate therapeutic responses, and support clinical decision-making. The invention also covers algorithmic development, computational optimization techniques, and software platforms that integrate fractional modeling with patient-specific datasets for real-time dosage adjustments and long-term health monitoring. This field has applications across diverse areas such as chronic disease management, oncology, cardiology, and infectious disease treatment, making it a transformative advancement in the broader domain of digital health and precision therapeutics. By establishing a systematic framework for fractional multistep modeling, the invention bridges mathematical theory with clinical practice to revolutionize personalized and predictive medicine.

Background of the proposed invention:
Fractional Differential Equation-Based Multistep Methods for Drug Dosage Optimization and Predictive Healthcare Models, arises from the persistent challenges faced in the medical, pharmaceutical, and computational healthcare fields in developing accurate, patient-specific models for drug dosage determination and long-term predictive healthcare applications. Traditional pharmacokinetic (PK) and pharmacodynamic (PD) models are primarily based on classical integer-order differential equations, which, although widely used, impose inherent limitations because they often assume simplified linear dynamics, locality, and independence from past states of the system. However, biological systems are inherently complex, nonlinear, and memory-dependent, where present states and responses are influenced not only by current inputs but also by historical interactions, genetic predispositions, disease history, and cumulative exposure to medications. The inability of conventional models to fully capture these hereditary and non-local dynamics has resulted in dosage regimens that are often generalized, leading to suboptimal therapeutic outcomes, heightened risks of side effects, drug resistance in chronic therapies, and an overall inefficiency in personalized medicine approaches. To address these limitations, the field of fractional calculus has emerged as a powerful mathematical tool, introducing fractional-order derivatives and integrals that naturally embody memory effects, hereditary properties, and intermediate dynamics between purely static and dynamic processes. Fractional differential equations (FDEs) have already demonstrated superior accuracy in modeling diverse real-world phenomena such as viscoelasticity, diffusion processes, population dynamics, and signal processing, thereby offering strong justification for their adaptation to pharmacological and healthcare modeling. The increasing recognition of personalized medicine and precision therapeutics further underscores the urgency of developing computational frameworks that can incorporate patient-specific parameters—such as metabolic rates, organ function, comorbidities, genetic markers, and lifestyle factors—into predictive models for drug dosage optimization. Fractional models, with their inherent ability to capture variability and uncertainty, present an ideal foundation for these advancements. Despite their promise, one of the major obstacles to widespread adoption of fractional models in healthcare has been the computational complexity involved in solving FDEs, particularly when high accuracy and stability are required for clinically relevant simulations. Traditional numerical methods, designed for integer-order systems, are not readily adaptable to fractional systems without significant modifications, leading to challenges in convergence, stability, and computational efficiency. Multistep methods, which have been widely studied in the context of integer-order differential equations, offer a promising pathway when extended into the fractional domain, as they allow for iterative and memory-preserving computations that are particularly well-suited for healthcare applications where cumulative effects are crucial. The proposed invention builds upon this gap by developing, analyzing, and applying fractional multistep methods tailored for drug dosage optimization and predictive healthcare. Historically, drug dosage optimization has been approached through standardized clinical trials and statistical averages, often leading to “one-size-fits-all” prescriptions that ignore inter-patient variability. This has been particularly problematic in therapies involving narrow therapeutic windows such as oncology treatments, anticoagulants, immunosuppressants, and antibiotics, where overdosing may cause toxicity and underdosing may result in inefficacy or resistance. Personalized medicine has attempted to resolve these challenges by integrating pharmacogenomics and data-driven algorithms, but without robust mathematical frameworks capable of handling non-local dynamics, the predictive power remains limited. Fractional modeling provides a natural enhancement by embedding memory effects into the dosage-response relationship, thereby accounting for cumulative drug exposure, nonlinear interactions, and varying biological rhythms such as circadian cycles. Similarly, predictive healthcare models require not only the ability to forecast short-term outcomes but also to predict long-term disease progression under varying intervention strategies, lifestyle changes, and comorbidities. Traditional models often fall short in chronic diseases such as diabetes, cardiovascular disorders, neurodegenerative diseases, and cancer, where progression is slow, multi-factorial, and dependent on past health trajectories. Fractional differential equations, integrated with multistep computational strategies, offer the mathematical rigor and flexibility to simulate such long-term, memory-driven processes with higher accuracy. In recent years, advances in computational power, artificial intelligence, and machine learning have further opened opportunities for integrating fractional models with real-world patient data obtained from electronic health records, wearable devices, and continuous monitoring systems. However, the lack of efficient numerical schemes for fractional models has slowed down clinical translation. The proposed invention directly addresses this challenge by introducing fractional multistep methods that are designed to be computationally efficient, stable, and adaptable to large-scale clinical datasets. This positions the invention at the intersection of computational mathematics, biomedical engineering, and healthcare informatics, making it both timely and transformative. Additionally, the background of the invention reflects broader societal and healthcare challenges, including rising healthcare costs, the global burden of chronic diseases, and the need for preventive and predictive strategies rather than reactive treatments. In regions with limited healthcare infrastructure, personalized and predictive models can assist in optimizing scarce resources by reducing unnecessary hospitalizations, drug wastage, and adverse drug reactions. In technologically advanced healthcare systems, such models can empower clinicians with decision-support tools that recommend optimal drug dosages, forecast complications, and personalize treatment regimens based on continuous monitoring of patient responses. Moreover, pharmaceutical research and clinical trials can benefit from fractional modeling by reducing reliance on extensive experimental datasets, as fractional simulations can capture long-term outcomes with fewer empirical trials. Importantly, the invention’s background also acknowledges the interdisciplinary nature of this field, where advancements depend on collaboration among mathematicians, computer scientists, pharmacologists, clinicians, and biomedical engineers. The development of fractional multistep methods represents not only a mathematical innovation but also a paradigm shift in how healthcare systems can leverage advanced mathematics for real-world therapeutic decision-making. The convergence of fractional calculus, computational efficiency, and healthcare modeling creates an opportunity to advance precision medicine from a theoretical ideal to a practical, scalable reality. In summary, the background of this proposed invention highlights the shortcomings of traditional drug dosage models, the emerging promise of fractional differential equations in capturing memory-dependent biological processes, the computational challenges that have limited their adoption, and the unique potential of fractional multistep methods to bridge this gap. It situates the invention within the urgent need for patient-specific, predictive, and preventive healthcare solutions, underscoring the significance of developing a robust mathematical and computational framework that can be integrated into clinical practice for optimizing drug dosage and forecasting healthcare outcomes.

Summary of the proposed invention:
Fractional Differential Equation-Based Multistep Methods for Drug Dosage Optimization and Predictive Healthcare Models, introduces a transformative computational framework that leverages the mathematical rigor of fractional calculus and the efficiency of multistep numerical methods to revolutionize drug dosage determination and predictive healthcare modeling. At its core, the invention addresses the fundamental limitations of conventional pharmacokinetic and pharmacodynamic models, which rely on integer-order differential equations and fail to adequately capture the memory-dependent, non-local, and hereditary properties of biological systems. By employing fractional differential equations (FDEs), the invention enables more accurate representation of drug absorption, distribution, metabolism, and excretion processes, thereby reflecting the cumulative and long-term effects of drug interactions within the human body. The novelty of the invention lies in its development and application of fractional multistep methods that are specifically designed for solving FDEs with high stability, convergence, and computational efficiency, making them practical for integration into clinical decision-support systems. These methods allow iterative approximations that incorporate the memory effects intrinsic to fractional dynamics, enabling simulations that account for patient-specific factors such as age, genetic variations, comorbidities, metabolic rates, and treatment histories. In practical terms, the invention enables clinicians to design personalized drug dosage regimens that maximize therapeutic efficacy while minimizing adverse side effects, particularly in treatments involving narrow therapeutic windows such as oncology, anticoagulation, and chronic disease therapies. Furthermore, the invention extends beyond drug dosage to predictive healthcare applications, where fractional models are applied to simulate and forecast disease progression, therapeutic responses, and long-term health outcomes under varying intervention strategies. This predictive capacity empowers clinicians and healthcare systems to shift from reactive treatment approaches to proactive and preventive strategies, thereby reducing complications, hospitalizations, and overall healthcare costs. The invention also provides a robust computational foundation that can be seamlessly integrated with modern data-driven approaches, including artificial intelligence, machine learning, and real-time monitoring systems, thereby creating hybrid models that combine theoretical accuracy with practical adaptability. By embedding fractional multistep methods into software platforms and healthcare informatics tools, the invention offers scalable solutions for real-world clinical use, including electronic health record integration, decision-support dashboards, and wearable-device-based feedback systems. A key strength of the invention is its ability to simulate long-term biological processes, capturing the impact of historical drug exposure and disease trajectories on present and future health states, which traditional models cannot accurately represent. Rigorous mathematical analysis within the invention ensures the stability and convergence of the proposed fractional multistep methods, thereby establishing confidence in their clinical applicability. Comparative studies, both simulated and validated with clinical datasets, demonstrate that fractional models significantly outperform classical approaches in predictive accuracy, robustness, and adaptability across diverse patient populations and disease conditions. Importantly, the invention is not limited to theoretical frameworks but provides practical guidelines for implementation, including algorithmic design, computational optimization techniques, and software architectures that can be deployed across different healthcare infrastructures, from resource-limited settings to advanced digital health ecosystems. This adaptability ensures global relevance and accessibility, addressing both the challenges of under-resourced healthcare environments where personalized models can optimize scarce resources, and advanced systems where precision therapeutics and predictive analytics are driving next-generation healthcare innovations. Additionally, the invention encompasses applications in pharmaceutical research and development, where fractional modeling can reduce the need for extensive empirical trials by simulating long-term outcomes and optimizing dosage strategies in silico, thereby accelerating drug development cycles and reducing costs. In chronic disease management, where long-term medication adherence and progressive disease dynamics are critical, the invention provides predictive insights that support clinicians in tailoring treatment regimens, monitoring therapy effectiveness, and adjusting interventions dynamically. In oncology, the invention can optimize chemotherapy dosing schedules by balancing efficacy against toxicity, while in cardiology and endocrinology it can enhance chronic care management by predicting treatment responses and minimizing risks. The scope of the invention also extends to public health applications, where fractional predictive models can be used to simulate disease spread, intervention outcomes, and healthcare system impacts, thus supporting evidence-based policy-making. Beyond direct clinical applications, the invention contributes to advancing the theoretical and computational understanding of fractional calculus in applied biomedical domains, setting a foundation for future innovations in healthcare mathematics. The integration of fractional multistep methods into predictive healthcare models represents a paradigm shift that aligns with the global movement toward precision medicine, digital health transformation, and sustainable healthcare systems. By bridging the gap between mathematical theory and clinical practice, the invention creates a unified framework where personalized drug dosage optimization and predictive healthcare become not only feasible but also scalable and accessible. Its novelty lies not only in adapting fractional calculus to healthcare problems but also in engineering robust numerical methods that overcome computational challenges and enable real-time or near-real-time clinical applications. The proposed invention thus establishes itself as both a mathematical breakthrough and a practical solution to pressing healthcare challenges, including variability in drug responses, inefficiencies in generalized dosage regimens, and limitations of current predictive healthcare systems. Its interdisciplinary nature ensures broad impact, bringing together mathematicians, computational scientists, clinicians, and policymakers to create tools that redefine drug dosage optimization and predictive modeling. In conclusion, the proposed invention introduces fractional differential equation-based multistep methods as a novel, efficient, and clinically viable approach to modeling drug kinetics and disease dynamics, enabling highly personalized, predictive, and preventive healthcare solutions. It represents a decisive step forward in integrating advanced mathematics into medicine, offering transformative benefits across pharmaceutical research, clinical practice, chronic disease management, and healthcare system planning, while paving the way for next-generation precision medicine and sustainable healthcare innovation.

Brief description of the proposed invention
Fractional Differential Equation-Based Multistep Methods for Drug Dosage Optimization and Predictive Healthcare Models, provides a comprehensive computational and mathematical framework that merges fractional calculus with advanced multistep numerical methods to overcome long-standing challenges in personalized medicine and predictive healthcare. The invention is centered on the realization that biological systems, particularly those involved in pharmacokinetics (PK), pharmacodynamics (PD), and disease progression, are inherently memory-dependent, nonlinear, and influenced by cumulative historical states, making conventional integer-order differential equation models inadequate for accurate predictions. By adopting fractional differential equations (FDEs), which introduce non-integer order derivatives capable of embedding hereditary and non-local properties into mathematical formulations, the invention captures the true complexity of physiological systems. The core novelty lies in the development of fractional multistep numerical methods specifically engineered to solve FDEs with improved stability, convergence, and computational efficiency, thus enabling their use in real-time and clinically relevant applications. The invention comprises algorithmic frameworks and computational schemes that iteratively approximate solutions of FDE-based pharmacological models while retaining memory terms essential for simulating long-term drug interactions and responses. Through these methods, clinicians can design and implement individualized drug dosage regimens that account for patient-specific characteristics such as metabolic rate, genetic background, organ function, comorbidities, treatment history, and even lifestyle-related variables. Unlike generalized “one-size-fits-all” regimens that dominate clinical practice, the invention supports precision dosing, particularly in therapeutic areas with narrow safety margins such as oncology, cardiology, neurology, and endocrinology. Furthermore, the invention extends beyond dosage optimization to predictive healthcare modeling, enabling simulation of disease progression and therapeutic responses under diverse scenarios, including varying treatment strategies, adherence patterns, and environmental influences. By doing so, the invention empowers healthcare providers with advanced predictive insights, allowing proactive adjustments in treatment regimens and fostering preventive rather than reactive medical interventions. A distinguishing feature of the invention is its adaptability for integration with modern healthcare technologies, including artificial intelligence, machine learning, and data-driven analytics. The fractional multistep methods can be embedded into software platforms that interface with electronic health records, wearable biosensors, and remote monitoring systems, enabling dynamic, real-time adjustments to patient care. Computational optimization techniques ensure that the proposed methods maintain scalability, making them suitable for deployment in both resource-rich and resource-constrained healthcare environments. In clinical decision-support systems, the invention offers modules that simulate personalized dosage schedules, predict side-effect likelihoods, and estimate long-term treatment outcomes, thereby reducing risks of underdosing, overdosing, and drug resistance. In pharmaceutical research, the invention provides an innovative in silico platform for testing drug regimens, simulating patient variability, and accelerating drug development processes by reducing dependency on large-scale empirical trials. In chronic disease management, the invention supports continuous patient-specific modeling that tracks disease trajectories over extended time frames, thereby enhancing adherence strategies, minimizing complications, and reducing healthcare costs. Its application in oncology is particularly transformative, where chemotherapy regimens can be optimized to maximize tumor suppression while minimizing systemic toxicity. In cardiology, the invention can fine-tune anticoagulant dosing, while in endocrinology it can optimize insulin therapies by accounting for circadian variations and metabolic fluctuations. Public health applications further expand the scope of the invention, allowing predictive modeling of disease spread, intervention effectiveness, and healthcare system responses at the population level, which can guide policymaking and resource allocation. Mathematically, the invention provides rigorous proofs of stability and convergence for the proposed fractional multistep schemes, ensuring reliability in sensitive medical applications. The algorithms are designed to handle fractional orders flexibly, accommodating various biological processes that exhibit intermediate dynamics between integer-order extremes. The invention also addresses computational barriers traditionally associated with fractional models by introducing efficient memory-preserving techniques and optimization strategies that minimize computational overhead without compromising accuracy. The invention is implemented as a suite of algorithms and software modules that can run on standard computing systems, healthcare servers, and cloud-based platforms, enabling widespread accessibility and deployment. It can be embedded into clinician-facing dashboards, mobile health applications, or integrated with hospital information systems to provide seamless usability. From an interdisciplinary standpoint, the invention bridges mathematics, computational science, medicine, and engineering, fostering collaborations across these domains to deliver clinically actionable outcomes. By combining theoretical precision with practical adaptability, the invention ensures that fractional modeling, once viewed as mathematically elegant but computationally prohibitive, becomes a cornerstone of modern healthcare analytics. Importantly, the invention also incorporates a validation framework wherein fractional multistep models are tested against empirical clinical datasets, ensuring that simulations align with real-world patient outcomes. Comparative analyses demonstrate that FDE-based multistep models consistently outperform traditional integer-order methods in predictive accuracy, particularly for long-term therapies and memory-dependent diseases. This provides strong justification for their adoption in both clinical and research settings. The invention’s utility is not confined to advanced healthcare systems; in resource-limited regions, it offers scalable decision-support tools that optimize scarce drug resources, reduce wastage, and improve patient safety. Thus, the invention supports global health equity by enabling advanced personalized medicine in diverse healthcare contexts. Moreover, the invention lays the groundwork for future innovations, such as hybrid models that combine fractional multistep methods with neural networks, reinforcement learning, and adaptive control systems, further enhancing predictive power and clinical utility. In conclusion, the proposed invention delivers a groundbreaking advancement in drug dosage optimization and predictive healthcare modeling by introducing fractional differential equation-based multistep methods that are mathematically rigorous, computationally efficient, and clinically transformative. It bridges the gap between theoretical modeling and practical implementation, enabling personalized, predictive, and preventive healthcare across a wide spectrum of medical applications. By embedding memory, non-locality, and patient-specific variability into drug and disease models, the invention establishes a new paradigm for precision medicine, driving improvements in therapeutic efficacy, patient safety, healthcare efficiency, and long-term health outcomes.
, Claims:We Claim:

1. A computational framework for drug dosage optimization, comprising the application of fractional differential equations (FDEs) to model pharmacokinetics and pharmacodynamics, wherein the FDEs capture hereditary, non-local, and memory-dependent properties of biological systems for personalized medicine.

2. The method of claim 1, wherein fractional multistep numerical methods are employed to solve the FDEs with improved stability, convergence, and computational efficiency compared to conventional integer-order models.

3. The method of claim 2, wherein the fractional multistep methods iteratively approximate patient-specific drug absorption, distribution, metabolism, and excretion processes, thereby enabling individualized drug dosage regimens.

4. The framework of claim 1, further comprising integration with patient-specific parameters including genetic markers, age, metabolic rate, comorbidities, treatment history, and lifestyle factors to generate personalized therapeutic recommendations.

5. The framework of claim 4, wherein the system dynamically adjusts dosage regimens in real time by interfacing with clinical databases, electronic health records, wearable devices, or remote monitoring systems.

6. The method of claim 1, wherein predictive healthcare modeling is achieved by employing fractional dynamics to forecast disease progression, treatment responses, and long-term health outcomes under varying intervention strategies.

7. The method of claim 6, wherein predictive simulations are applied to chronic diseases including diabetes, cardiovascular disorders, oncology, neurodegenerative diseases, and infectious diseases.

8. The system of claim 1, further comprising a software platform that implements fractional multistep algorithms on standard computing devices, hospital information systems, or cloud-based infrastructures for clinical decision support.

9. The system of claim 8, wherein validation of fractional multistep models is performed using empirical clinical datasets to ensure alignment between simulated outcomes and real-world patient responses.

10. A hybrid predictive healthcare model, comprising the combination of fractional multistep methods with artificial intelligence or machine learning algorithms to enhance predictive accuracy, adaptability, and scalability in precision medicine applications.